Cinclus Pharma Holding ABFRA:J8P +1.03%4 Gross Margin % is 0.00% as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 4/100. The stock has 3 warning signs investors should review. Among 936 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 106837.5% on this metric.
The historical rank and industry rank for Cinclus Pharma Holding AB's Gross Margin % or its related term are showing as below:
FRA:J8P's Gross Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 48.5 * Ranked among companies with meaningful Gross Margin % only.
Cinclus Pharma Holding AB had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Cinclus Pharma Holding AB (FRA:J8P) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cinclus Pharma Holding AB had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cinclus Pharma Holding AB Gross Margin % Related Terms
Cinclus Pharma Holding AB Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cinclus Pharma Holding AB Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cinclus Pharma Holding AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cinclus Pharma Holding AB (FRA:J8P) has a Gross Margin % of 0.00% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 936 companies in the Drug Manufacturers industry.
Is Cinclus Pharma Holding AB's Gross Margin % too high?
Cinclus Pharma Holding AB's current Gross Margin % is 0.00%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #999999 out of 936 companies for Gross Margin %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median Gross Margin % is 48.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Gross Margin % of 0.00%. The current Gross Margin % is 0.00%. Cinclus Pharma Holding AB's overall GF Score™ is 4/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Gross Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
4GF Score
Get the complete analysis for FRA:J8P
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8P has been successfully added to your 
